ADBiotech（A179530）株式概要ADBiotech Co, Ltd.は、家畜、水産、ヒト用の抗体を開発し、韓国内外で販売している。 詳細A179530 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間24.5%減少しました。 KR市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( ₩56B )すべてのリスクチェックを見るA179530 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩2.83k519.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8b15b2016201920222025202620282031Revenue ₩14.6bEarnings ₩2.1bAdvancedSet Fair ValueView all narrativesADBiotech Co., Ltd. 競合他社MYUNGMOON PharmLtdSymbol: KOSE:A017180Market cap: ₩53.4bJin Yang PharmaceuticalSymbol: KOSDAQ:A007370Market cap: ₩60.4bKorea Arlico PharmLtdSymbol: KOSDAQ:A260660Market cap: ₩47.7bEnzychem LifesciencesSymbol: KOSDAQ:A183490Market cap: ₩76.4b価格と性能株価の高値、安値、推移の概要ADBiotech過去の株価現在の株価₩2,830.0052週高値₩5,450.0052週安値₩1,300.00ベータ0.181ヶ月の変化5.20%3ヶ月変化76.00%1年変化46.10%3年間の変化-31.06%5年間の変化-74.62%IPOからの変化-44.87%最新ニュースお知らせ • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).お知らせ • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listingお知らせ • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.お知らせ • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct ListingNew Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).最新情報をもっと見るRecent updatesお知らせ • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).お知らせ • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listingお知らせ • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.お知らせ • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct ListingNew Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).お知らせ • Jun 10ADBiotech Co., Ltd. announced that it expects to receive KRW 8.285 billion in fundingADBiotech Co., Ltd. announces a private placement to issue 5,000,000 Common Shares at a price of KRW 1,657 for gross proceeds of KRW 8,285,000,000 on June 9, 2025. Expected closing date of the offering is October 31, 2025.New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩28.2b market cap, or US$20.9m).お知らせ • Jun 09+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 5.646828991 billion in funding from OQPBIOM INC.ADBiotech Co., Ltd. announced a private placement to issue 3,407,863 common shares at an issue price of KRW 1,657 per share for gross proceeds of KRW 5,646,828,991 on June 9, 2025. The transaction will include participation from new investor OQPBIOM INC. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on August 29, 2025.New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.3b free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩21.0b market cap, or US$15.2m).New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩19.8b market cap, or US$13.8m).Reported Earnings • Mar 26Full year 2024 earnings released: ₩870 loss per share (vs ₩313 loss in FY 2023)Full year 2024 results: ₩870 loss per share (further deteriorated from ₩313 loss in FY 2023). Revenue: ₩11.1b (up 6.3% from FY 2023). Net loss: ₩7.95b (loss widened 178% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year whereas the company’s share price has fallen by 44% per year.New Risk • Mar 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.0b (US$8.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Market cap is less than US$10m (₩13.0b market cap, or US$8.92m).お知らせ • Mar 18ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩22.4b market cap, or US$15.5m).お知らせ • Dec 26ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion. Security Name: Common Stocks Security Type: Common Stock Securities Offered: 4,026,171 Price\Range: KRW 1987分析記事 • Dec 20Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩24.9b market cap, or US$17.3m).New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩171m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩171m free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩25.1b market cap, or US$18.0m).New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩39.1b market cap, or US$29.4m).分析記事 • Sep 02Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩30.1b market cap, or US$21.8m).お知らせ • Apr 26+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,LtdADBiotech Co., Ltd. announced a private placement to issue Series 6 Bearer Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 4,500,000,000 on April 25, 2024. KB Securities Co., Ltd. (In the position of fiduciary of Fund 1) for KRW 200,000,000, Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 2) for KRW 300,000,000, KB Securities Co., Ltd. (In the position of trustee of Fund 3) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 4) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 5) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 6)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 7) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 8) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 9)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 10) for KRW 300,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 11) for KRW 350,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 12) for KRW 700,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 13) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 14)) for KRW 500,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 15) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 16) for KRW 150,000,000 and Kiwoom Securities Co., Ltd. for KRW 500,000,000. The transaction has been approved by the shareholders the company and is expected to close on April 26, 2024. The bonds are 100% convertible into 1,765,398 shares at a fixed conversion price of KRW 2,549 from April 26, 2025 to March 26, 2027. The bonds bear 0 coupon rate and 1% maturity rate and matures on April 26, 2029.Reported Earnings • Mar 22Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)Full year 2023 results: ₩313 loss per share (down from ₩297 profit in FY 2022). Revenue: ₩10.5b (down 1.5% from FY 2022). Net loss: ₩2.86b (down 206% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩4,060, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 48% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,320, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$25.1m).Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,645, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)Third quarter 2023 results: ₩104 loss per share (further deteriorated from ₩29.00 loss in 3Q 2022). Revenue: ₩2.76b (up 48% from 3Q 2022). Net loss: ₩947.1m (loss widened 258% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 148% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,475, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 41% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩4,910, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 20% over the past three years.お知らせ • Jan 17ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion on January 13, 2023. Under the terms ADBiotech Co., Ltd. acquired 2,578,252 shares comprising of 34,451 shares of common stock and 2,543,801 shares of preferred stock. Post completion, ADBiotech Co., Ltd will own 3,528,252 shares representing 28.07% stake. The board of ADBiotech Co., Ltd. passed resolution for the transaction on January 13, 2023 and the transaction is expected to complete on January 17, 2023.お知らせ • May 05ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in fundingOn May 3, 2021, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.お知らせ • Apr 24ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue series 5 registered non-guaranteed private convertible bonds for KRW 4,500,000,000 on April 22, 2021. The transaction will include participation from A-Stone Project 1 Fund for 2,500,000,000, Magna VITA Fund for KRW 700,000,000, Focus Super Rich Hedge Fund 5 for KRW 400,000,000, and other investors. The bonds carry no coupon and yield, and will mature on May 3, 2024. The bonds are 100% convertible into 170,240 common shares of the company representing 6.64% stake at the conversion price of KRW 26,433 per share. The conversion period will start from May 3, 2022 and May 2, 2024. The transaction is expected to close on May 3, 2021. The transaction has been approved by the board of directors of the company.お知らせ • Feb 27ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 14New 90-day high: ₩26,700The company is up 48% from its price of ₩18,000 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 09New 90-day high: ₩22,950The company is up 28% from its price of ₩17,950 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day high: ₩20,000The company is up 32% from its price of ₩15,200 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 19New 90-day high: ₩19,950The company is up 33% from its price of ₩15,000 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Sep 21New 90-day high: ₩19,000The company is up 16% from its price of ₩16,450 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 32% over the same period.お知らせ • Jul 18ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.On July 9, 2020, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.お知らせ • Jul 02ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue 4th series named non-guaranteed private equity bonds for KRW 1,000,000,000 on June 30, 2020. The transaction will include participation from new investor IDV-IP Fisheries Professional Fund No. 2. The bonds bears an interest of 3% per annum and will mature on July 09, 2025. The bonds are 100% convertible into 56,179 common shares of the company representing 2.42% stake at the conversion price of KRW 17,800 per share. The conversion period will start from July 10, 2021 and ends on July 08, 2025. The subscription date for bonds is June 30, 2020 and payment date is July 09, 2020. The transaction has been approved by the board of directors of the company.お知らせ • Jun 30ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.ADBiotech Co., Ltd. (XKON:A179530) announced a private placement of 206,897 convertible preferred shares at a price of KRW 14,500 per share for gross proceeds of KRW 3,000,006,500 on June 29, 2020. The transaction will include participation from SBI-Growth Ladder Konex Vitalization Fund No.2, a fund managed by returning investor SBI Investment Korea Co., Ltd. (KOSDAQ:A019550). The conversion period is between July 10, 2020 and July 09, 2030. The preferred shares are convertible into 206,897 common shares. The shares are redeemable. The repayment period is between July 10, 2023 and July 09, 2030.The transaction has been approved by the board of directors. The payment date is July 9, 2020.株主還元A179530KR PharmaceuticalsKR 市場7D14.1%-0.9%4.6%1Y46.1%27.3%186.7%株主還元を見る業界別リターン: A179530過去 1 年間で27.3 % の収益を上げたKR Pharmaceuticals業界を上回りました。リターン対市場: A179530は、過去 1 年間で186.7 % のリターンを上げたKR市場を下回りました。価格変動Is A179530's price volatile compared to industry and market?A179530 volatilityA179530 Average Weekly Movement17.2%Pharmaceuticals Industry Average Movement7.3%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%安定した株価: A179530の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A179530の weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200059Hong-Gul Cheongadbiotech.comADBiotech Co., Ltd.は、家畜、水産、ヒト用の抗体を開発し、韓国内外で販売している。抗生物質、殺菌剤、蠕虫、市販薬、補助飼料、代謝性医薬品を提供。また、健康機能性食品や加工食品も提供している。Ltd.は2000年に設立され、韓国の春川市に本社を置く。もっと見るADBiotech Co., Ltd. 基礎のまとめADBiotech の収益と売上を時価総額と比較するとどうか。A179530 基礎統計学時価総額₩55.69b収益（TTM）-₩3.30b売上高(TTM)₩12.90b4.3xP/Sレシオ-16.9xPER（株価収益率A179530 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A179530 損益計算書（TTM）収益₩12.90b売上原価₩7.75b売上総利益₩5.15bその他の費用₩8.45b収益-₩3.30b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-167.89グロス・マージン39.92%純利益率-25.62%有利子負債／自己資本比率109.0%A179530 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 02:53終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ADBiotech Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).
お知らせ • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.
お知らせ • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct Listing
New Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).
お知らせ • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).
お知らせ • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.
お知らせ • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct Listing
New Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).
お知らせ • Jun 10ADBiotech Co., Ltd. announced that it expects to receive KRW 8.285 billion in fundingADBiotech Co., Ltd. announces a private placement to issue 5,000,000 Common Shares at a price of KRW 1,657 for gross proceeds of KRW 8,285,000,000 on June 9, 2025. Expected closing date of the offering is October 31, 2025.
New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩28.2b market cap, or US$20.9m).
お知らせ • Jun 09+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 5.646828991 billion in funding from OQPBIOM INC.ADBiotech Co., Ltd. announced a private placement to issue 3,407,863 common shares at an issue price of KRW 1,657 per share for gross proceeds of KRW 5,646,828,991 on June 9, 2025. The transaction will include participation from new investor OQPBIOM INC. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on August 29, 2025.
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.3b free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩21.0b market cap, or US$15.2m).
New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩19.8b market cap, or US$13.8m).
Reported Earnings • Mar 26Full year 2024 earnings released: ₩870 loss per share (vs ₩313 loss in FY 2023)Full year 2024 results: ₩870 loss per share (further deteriorated from ₩313 loss in FY 2023). Revenue: ₩11.1b (up 6.3% from FY 2023). Net loss: ₩7.95b (loss widened 178% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year whereas the company’s share price has fallen by 44% per year.
New Risk • Mar 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.0b (US$8.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Market cap is less than US$10m (₩13.0b market cap, or US$8.92m).
お知らせ • Mar 18ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩22.4b market cap, or US$15.5m).
お知らせ • Dec 26ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion. Security Name: Common Stocks Security Type: Common Stock Securities Offered: 4,026,171 Price\Range: KRW 1987
分析記事 • Dec 20Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩24.9b market cap, or US$17.3m).
New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩171m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩171m free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩25.1b market cap, or US$18.0m).
New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩39.1b market cap, or US$29.4m).
分析記事 • Sep 02Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩30.1b market cap, or US$21.8m).
お知らせ • Apr 26+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,LtdADBiotech Co., Ltd. announced a private placement to issue Series 6 Bearer Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 4,500,000,000 on April 25, 2024. KB Securities Co., Ltd. (In the position of fiduciary of Fund 1) for KRW 200,000,000, Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 2) for KRW 300,000,000, KB Securities Co., Ltd. (In the position of trustee of Fund 3) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 4) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 5) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 6)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 7) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 8) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 9)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 10) for KRW 300,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 11) for KRW 350,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 12) for KRW 700,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 13) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 14)) for KRW 500,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 15) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 16) for KRW 150,000,000 and Kiwoom Securities Co., Ltd. for KRW 500,000,000. The transaction has been approved by the shareholders the company and is expected to close on April 26, 2024. The bonds are 100% convertible into 1,765,398 shares at a fixed conversion price of KRW 2,549 from April 26, 2025 to March 26, 2027. The bonds bear 0 coupon rate and 1% maturity rate and matures on April 26, 2029.
Reported Earnings • Mar 22Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)Full year 2023 results: ₩313 loss per share (down from ₩297 profit in FY 2022). Revenue: ₩10.5b (down 1.5% from FY 2022). Net loss: ₩2.86b (down 206% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩4,060, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 48% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,320, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.
New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$25.1m).
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,645, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)Third quarter 2023 results: ₩104 loss per share (further deteriorated from ₩29.00 loss in 3Q 2022). Revenue: ₩2.76b (up 48% from 3Q 2022). Net loss: ₩947.1m (loss widened 258% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 148% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,475, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 41% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩4,910, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 20% over the past three years.
お知らせ • Jan 17ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion on January 13, 2023. Under the terms ADBiotech Co., Ltd. acquired 2,578,252 shares comprising of 34,451 shares of common stock and 2,543,801 shares of preferred stock. Post completion, ADBiotech Co., Ltd will own 3,528,252 shares representing 28.07% stake. The board of ADBiotech Co., Ltd. passed resolution for the transaction on January 13, 2023 and the transaction is expected to complete on January 17, 2023.
お知らせ • May 05ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in fundingOn May 3, 2021, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.
お知らせ • Apr 24ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue series 5 registered non-guaranteed private convertible bonds for KRW 4,500,000,000 on April 22, 2021. The transaction will include participation from A-Stone Project 1 Fund for 2,500,000,000, Magna VITA Fund for KRW 700,000,000, Focus Super Rich Hedge Fund 5 for KRW 400,000,000, and other investors. The bonds carry no coupon and yield, and will mature on May 3, 2024. The bonds are 100% convertible into 170,240 common shares of the company representing 6.64% stake at the conversion price of KRW 26,433 per share. The conversion period will start from May 3, 2022 and May 2, 2024. The transaction is expected to close on May 3, 2021. The transaction has been approved by the board of directors of the company.
お知らせ • Feb 27ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 14New 90-day high: ₩26,700The company is up 48% from its price of ₩18,000 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 09New 90-day high: ₩22,950The company is up 28% from its price of ₩17,950 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day high: ₩20,000The company is up 32% from its price of ₩15,200 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 19New 90-day high: ₩19,950The company is up 33% from its price of ₩15,000 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Sep 21New 90-day high: ₩19,000The company is up 16% from its price of ₩16,450 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 32% over the same period.
お知らせ • Jul 18ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.On July 9, 2020, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.
お知らせ • Jul 02ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue 4th series named non-guaranteed private equity bonds for KRW 1,000,000,000 on June 30, 2020. The transaction will include participation from new investor IDV-IP Fisheries Professional Fund No. 2. The bonds bears an interest of 3% per annum and will mature on July 09, 2025. The bonds are 100% convertible into 56,179 common shares of the company representing 2.42% stake at the conversion price of KRW 17,800 per share. The conversion period will start from July 10, 2021 and ends on July 08, 2025. The subscription date for bonds is June 30, 2020 and payment date is July 09, 2020. The transaction has been approved by the board of directors of the company.
お知らせ • Jun 30ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.ADBiotech Co., Ltd. (XKON:A179530) announced a private placement of 206,897 convertible preferred shares at a price of KRW 14,500 per share for gross proceeds of KRW 3,000,006,500 on June 29, 2020. The transaction will include participation from SBI-Growth Ladder Konex Vitalization Fund No.2, a fund managed by returning investor SBI Investment Korea Co., Ltd. (KOSDAQ:A019550). The conversion period is between July 10, 2020 and July 09, 2030. The preferred shares are convertible into 206,897 common shares. The shares are redeemable. The repayment period is between July 10, 2023 and July 09, 2030.The transaction has been approved by the board of directors. The payment date is July 9, 2020.
